How many drugs treat Breast Cancer?

Drug Landscape tracks 6 marketed treatments for Breast Cancer (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/breast-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Breast Cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Breast Cancer (Oncology) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Oncology 6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Breast Cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Paraplatin	Carboplatin	MYLAN SEIYAKU Ltd	Platinum-containing alkylating agent	DNA	1989-01-01
Technetium Tc 99M Sestamibi	TECHNETIUM	Cyclomedica	Radioactive Diagnostic Agent [EPC]		1981-01-01
Talzenna	Talazoparib Tosylate	Pfizer Inc.	PARP inhibitor	PARP1 and PARP2 enzymes
PF-07850327, ARV-471, vepdegestrant	pf-07850327-arv-471-vepdegestrant	Pfizer	Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)	Estrogen Receptor (ER)
Tumor Tissue	tumor-tissue	Pfizer	Not specified	Not specified
Paraplatin	Paraplatin	ARCAGY/ GINECO GROUP

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Breast Cancer
Pfizer Inc. · 2 drugs in Breast Cancer
ARCAGY/ GINECO GROUP · 1 drug in Breast Cancer
Cyclomedica · 1 drug in Breast Cancer
MYLAN SEIYAKU Ltd · 1 drug in Breast Cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Breast Cancer:

Cite this brief

Drug Landscape (2026). Breast Cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/breast-cancer. Accessed 2026-06-10.

Breast Cancer full disease profile — treatment pathway, diagnostics, guidelines
Oncology area landing
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing